Molecular Insight Pharmaceuticals (MIPI)

SUMMARY

BULLS

BEARS

DATA CENTRAL

Day
52 Wk

Molecular Insight Pharmaceuticals, Inc. Presents Clinical Data on Prostate Cancer Diagnostic

Market Wire Jun 16

CAMBRIDGE, MA -- (Marketwire) -- 06/16/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today presented clinical data on a radiolabeled, small-molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate

Molecular Insight Pharma (MIPI) Presents Clincial Data on Trofex(TM), a Prostate Cancer Diagnostic

StreetInsider.com Jun 16

Molecular Insight Pharmaceuticals, Inc. to Present at Jefferies Healthcare Conference

Market Wire Jun 11

CAMBRIDGE, MA -- (Marketwire) -- 06/11/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) will present at the Jefferies 3rd Annual Healthcare Conference in New York City on June 18, 2009 at 4:15 PM, Eastern Standard Time. The Company will

Molecular Insight Pharmaceuticals, Inc. to Present Clinical, Preclinical Data at the Society of Nuclear Medicine 2009 Annual Meeting

Market Wire Jun 10

CAMBRIDGE, MA -- (Marketwire) -- 06/10/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) researchers will present data on the Company's progress in developing novel radiopharmaceuticals that may provide a promising option for molecular

Molecular Insight Pharmaceuticals Announces Inducement Grant for CEO Under NASDAQ Marketplace Rule 4350

Market Wire May 15

CAMBRIDGE, MA -- (Marketwire) -- 05/15/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that in connection with its hiring of Daniel L. Peters as its President and Chief Executive Officer, and as reported in its Current

Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval to Proceed With Phase 3 Development of Onalta(TM)

Market Wire May 14

CAMBRIDGE, MA -- (Marketwire) -- 05/14/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced that the European Medicines Agency (EMEA) has approved its Phase 3 protocol for Onalta (Yttrium-90 edotreotide). Onalta is the

Molecular Insight Pharmaceuticals Expands Management Team by Appointing Daniel L. Peters as President and Chief Executive Officer

Market Wire May 13

CAMBRIDGE, MA -- (Marketwire) -- 05/13/09 -- The Board of Directors of Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that Daniel L. Peters has been appointed President and Chief Executive Officer. Mr. Peters was also elected

Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2009 Financial and Operational Results

Market Wire May 11

CAMBRIDGE, MA -- (Marketwire) -- 05/11/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced the financial results for the first quarter ended March 31, 2009. In a conference call scheduled for today at 2:00 p.m., Eastern Time,

Molecular Insight Pharmaceuticals, Inc. to Announce First Quarter Financial Results on May 11, 2009

Market Wire May 4

CAMBRIDGE, MA -- (Marketwire) -- 05/04/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will release its first quarter 2009 financial results before the opening of the Market and will hold a conference call on

The Magic of ‘Product Substitution’

Contrarian Profits May 5

It is this last fraud that has been used to such success by Mogambo Inter-Planetary Industries (MIPI), by which we commit an as-yet legalized extortion by utilizing the word 'improved'. John Williams of shadowstats.com is quoted in an interview...

Suggest other news sources for this topic


	Suggest a News Source Topic Top news source/blog that we're missing Why do you recommend this news source? Close Thanks for your suggestion!

The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.

[edit] References

Retrieved from "http://www.wikinvest.com/stock/Molecular_Insight_Pharmaceuticals_(MIPI)"

Categories: Pharma & Healthcare | Biotechnology

Worried about pump and dump?

We review changes
for stock spam

» read more

Want to make Wikinvest better?

We need your help,
contribute today

» learn how

Do you write software?

We are recruiting
the best engineers

» view jobs

Like Wikinvest?

Spread the word —
Tell your friends!

» spread the word

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.